Testing a New Drug for Recurring Blood Cell Cancer

Plain-English translation of NCT06311227 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called to treat hairy cell leukemia that has returned or progressed after earlier treatments. is a pill you would take by mouth once daily for up to 19 months. The trial wants to see how many patients respond to this medication and how well it works compared to standard options.

Hairy cell leukemia can come back even after successful initial treatment, and some patients cannot take or do not respond to other available drugs. This trial is exploring whether this medication could offer hope to patients in that difficult situation.

Do you qualify?

You likely qualify if…

you have been diagnosed with hairy cell leukemia or hairy cell leukemia variant that has returned after previous purine analog therapy
you are either ineligible for or have relapsed from BRAF-targeted therapy
you have not received this specific medication before
you are at least 18 years old
your liver and kidney function tests are within acceptable ranges
you have a clear medical need for treatment based on your blood cell counts or disease burden

You likely don't qualify if…

you are currently pregnant or breastfeeding, or unwilling to use contraception during and for 30 days after treatment
you have active or uncontrolled heart disease or are in poor cardiac condition
you have severe liver disease or kidney dysfunction beyond what the trial allows
you have untreated or uncontrolled infections, including HIV or hepatitis without appropriate management

What participation looks like

You would take the medication by mouth once daily for cycles of 28 days, continuing for up to 19 cycles unless your disease worsens or side effects become unmanageable. Throughout the trial, you would have regular blood tests and imaging scans (CT or MRI) to monitor how you're responding. You may also have bone marrow biopsies and, if needed, spinal taps to check for disease involvement in the fluid around your spine. After you finish treatment, you'll have a follow-up visit 30 days later.

AI-generated summary from trial data · Jul 20, 2026 · Not medical advice

Trial locations(21 sites)

United States

City of Hope Comprehensive Cancer Center, Duarte, California

City of Hope at Irvine Lennar, Irvine, California

UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida

UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs, Florida